Attributable burden in patients with carbapenem-nonsusceptible gram-negative respiratory infections

Ying P. Tabak¹, Anita Sung², Gang Ye¹, Latha Vankeepuram¹, Vikas Gupta¹, Eilish McCann²

¹ Digital Health, Medical Affairs, Becton, Dickinson and Company, Franklin Lakes, New Jersey, United States of America, ² Center for Observational and Real-World Evidence (CORE), Merck & Co., Inc., Kenilworth, New Jersey, United States of America

* Eilish.mccann@merck.com

Abstract

Objective
We aimed to describe the clinical and economic burden attributable to carbapenem-nonsusceptible (C-NS) respiratory infections.

Methods
This retrospective matched cohort study assessed clinical and economic outcomes of adult patients (aged ≥18 years) who were admitted to one of 78 acute care hospitals in the United States with nonduplicate C-NS and carbapenem-susceptible (C-S) isolates from a respiratory source. A subset analysis of patients with principal diagnosis codes denoting bacterial pneumonia or other diagnoses was also conducted. Isolates were classified as community- or hospital-onset based on collection time. A generalized linear mixed model method was used to estimate the attributable burden for mortality, 30-day readmission, length of stay (LOS), cost, and net gain/loss (payment minus cost) using propensity score-matched C-NS versus C-S cohorts.

Results
For C-NS cases, mortality (25.7%), LOS (29.4 days), and costs ($81,574) were highest in the other principal diagnosis, hospital-onset subgroup; readmissions (19.4%) and net loss ($-9522) were greatest in the bacterial pneumonia, hospital-onset subgroup. Mortality and readmissions were not significantly higher for C-NS cases in any propensity score-matched subgroup. Significant C-NS-attributable burden was found for both other principal diagnosis subgroups for LOS (hospital-onset: 3.7 days, \(P = 0.006\); community-onset: 1.5 days, \(P<0.001\)) and cost (hospital-onset: $12,777, \(P<0.01\); community-onset: $2681, \(P<0.001\)).
Conclusions
Increased LOS and cost burden were observed in propensity score-matched patients with C-NS compared with C-S respiratory infections; the C-NS–attributable burden was significant only for patients with other principal diagnoses.

Introduction
Respiratory infections, such as bacterial pneumonia, rank among the leading causes of mortality in the United States (U.S.) and are responsible for more than 900,000 hospitalizations each year [1,2]. While the proportion of hospitalizations related to pneumonia appears to be declining, a study found that hospitalization rates for bacterial pneumonia caused by 2 gram-negative pathogens (Klebsiella and Pseudomonas spp.) increased significantly from 2002 through 2011 (by 35% and 23%, respectively; P<0.001) [3,4]. In addition, gram-negative pathogens are commonly implicated in hospital-acquired bacterial pneumonia [5,6].

Guideline-recommended antibiotics for the empiric treatment of gram-negative respiratory infections include antipseudomonal penicillins, cephalosporins, carbapenems, monobactams, fluoroquinolones, aminoglycosides, and polymyxins [7,8]. Despite the array of antibiotic classes available for the treatment of these infections, antibiotic resistance is an ongoing and increasing global health problem that reduces treatment options [9]. Antibiotic resistance is estimated to result in 23,000 deaths each year in the U.S., with an estimated additional cost to the healthcare system of $20 billion annually [10]. Several antimicrobial surveillance programs of respiratory isolates have documented decreased susceptibility to a variety of antibiotics, including the carbapenem class [5,11,12].

Carbapenem-nonsusceptible (C-NS) isolates from any infection source are associated with poor patient outcomes, including fewer resolved infections after 1 month, increased hospital length of stay (LOS), and increased risk of mortality [13–16]. In this study we examined the clinical and economic impact specific to respiratory infections due to culture-confirmed gram-negative C-NS pathogens. In particular, we compared the burden of C-NS infections with that of carbapenem-susceptible (C-S) infections in a retrospective analysis of microbiological and administrative data from 78 U.S. hospitals.

Materials and methods
Data source
For this retrospective matched cohort study of adult patients aged ≥18 years who were admitted to one of 78 U.S. acute care hospitals with respiratory source isolates that were C-NS or C-S, we used the BD Insights Research Database (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) to obtain electronically captured patient-level microbiological and administrative data [17–19]. The dataset was collected from January 1, 2013, to September 30, 2015, prior to the transition from the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) to the 10th version in the U.S., and included microbiological data (specimen collection time, source, and culture and susceptibility results), hospital data, and post-discharge administrative data (principal diagnosis, discharge disposition, payer, hospital LOS, hospital cost, and payment received by the hospital). The study dataset was a de-identified and limited retrospective dataset exempted from patient consent by the New England Institutional Review Board (Wellesley, MA, USA).
Study population
Nonduplicate (the first isolate of any species obtained from a patient per 30-day period) respiratory isolates from adult in-patients that were tested for carbapenem susceptibility were included in the study. Patients were stratified by their principal ICD-9-CM diagnosis code and a subset of patients had an ICD-9-CM code that denoted bacterial pneumonia (S1 Table).

Definitions
Carbapenem-nonsusceptible versus carbapenem-susceptible cases. Gram-negative respiratory isolates were classified as C-NS if they were determined to be “resistant” or “intermediate” to imipenem or meropenem for \textit{Pseudomonas aeruginosa} or \textit{Acinetobacter baumannii} (as ertapenem is intrinsically not active against these pathogens), or to imipenem, meropenem, or ertapenem for \textit{Enterobacteriaceae} (new taxonomy: \textit{Enterobacterales}): \textit{Escherichia coli}, \textit{Klebsiella pneumoniae}, \textit{Proteus mirabilis}, \textit{Enterobacter cloacae}, \textit{Enterobacter aerogenes}, \textit{Serratia marcescens}, \textit{Citrobacter freundii}, \textit{Morganella morganii}. Procedures and systems used for susceptibility testing and microbiological reporting could be variable across institutions. The definitions of “resistant” or “intermediate” were determined using the interpretative results for each hospital report in the laboratory information system.

Infection-onset period. Specimen collection time (<3 versus ≥3 days from hospital admission) dictated the classification of isolates as either community-onset or hospital-onset, respectively.

Statistical analysis
Propensity score matching. Four subgroups sorted by 1) principal diagnosis (bacterial pneumonia versus other) and 2) infection-onset period (community-onset versus hospital-onset) were created: Group 1, bacterial pneumonia, community-onset; Group 2, bacterial pneumonia, hospital-onset; Group 3, other principal diagnosis, community-onset; Group 4, other principal diagnosis, hospital-onset. Using C-NS and C-S as a binary variable, a propensity score model was developed for each of the 4 subgroups, thereby permitting adjustment of potential confounders. The propensity models included the following potential confounding factors: age, sex, payer, intensive care unit admission status, mechanical ventilation status, principal diagnosis-based disease categories (using the Clinical Classification Software [CCS] categories [for other principal diagnosis subgroups only]) [20], type of gram-negative organism(s), exposure risk (number of days from admission to onset of infection [for hospital-onset subgroups only]), number of hospital admissions in the 90 days before the index admission, and hospital attributes (teaching status, hospital size, geographic location). We also included an Acute Laboratory Risk of Mortality Score (ALaRMS) as an aggregate measure of clinical severity [21]. The ALaRMS uses patient demographics and 23 numeric laboratory test results to score the probability of in-hospital mortality. Laboratory parameters assessed include serum chemistry (albumin, aspartate transaminase, alkaline phosphatase, blood urea nitrogen, calcium, creatinine, glucose, potassium, sodium, and total bilirubin), hematology and coagulation parameters (bands, hemoglobin, partial thromboplastin time, prothrombin time, international normalized ratio, platelets, and white blood cell count), arterial blood gas (partial pressure of carbon dioxide, partial pressure of oxygen, and pH value), and cardiac markers (brain natriuretic peptide, creatinine phosphokinase-MB, pro-brain natriuretic peptide, and troponin I or troponin T).

Based on the propensity score generated using the aforementioned parameters, C-NS cases were matched with C-S cases by applying the Greedy 1-to-1 nearest-neighbor matching algorithm within each subgroup [22]. The matching caliper used for each propensity score
matching program was 0.25. For both the matched C-NS and C-S cases, outcomes were compared within each subgroup to ensure comparability.

Outcomes. In-hospital mortality, 30-day readmission, LOS, cost, and net gain/loss, defined as total payment received minus total cost, were the outcomes of interest for this study.

Estimating attributable clinical and economic burden. C-NS–attributable burden for each outcome was estimated using the generalized linear mixed model (GLMM) method on the propensity score-matched C-NS and C-S cases within each subgroup. Inter-hospital variations and skewed distributions were accounted for by the GLMM approach. Specifically, we used the random intercept logistic regression models (a special form of GLMM) for the 2 categorical outcomes of in-hospital mortality and 30-day readmission. For the continuous outcomes—LOS, cost, and net gain/loss—we used the regular GLMM with the gamma distribution as the transformation function and "hospital" as the random effect. $P$ values $<0.05$ were viewed as statistically significant. All analyses were conducted using the Statistical Analysis System (SAS) version 9.4 (SAS Institute, Cary, NC, USA).

Results

Patient characteristics

Carbapenem susceptibility testing results were available for 6830 admissions with gram-negative isolates from a respiratory source. Of those, 724 had principal diagnosis codes denoting bacterial pneumonia (Group 1, 572 community-onset; Group 2, 152 hospital-onset) and 6106 had another principal diagnosis (Group 3, 3583 community-onset; Group 4, 2523 hospital-onset) (Fig 1).

Baseline characteristics for each subgroup, sorted by propensity score matching for C-NS versus C-S, are shown in Table 1 (S2 Table shows characteristics before and after matching). After matching, each subgroup contained equal numbers of C-NS and C-S cases (Group 1, 101; Group 2, 42; Group 3, 742; Group 4, 463). Within each of the 4 subgroups, the potential confounding factors were largely balanced. In the overall matched cohort, most patients were $\geq 55$ years of age, and $P. \ aeruginosa$ was the pathogen type observed most frequently (57.5%-82.2%), followed by "other gram-negative" (5.9%-27.4%) and polymicrobial infections (0%-15.1%). Most patients had an ALaRMS score in the first, second, or third quartile (59.5%-81.9%). Higher proportions of patients with an ALaRMS score in the fourth quartile (denoting the highest in-hospital mortality risk) were observed in the hospital-onset subgroups (27.6% and 40.5% for Groups 2 and 4, respectively) versus community-onset subgroups (18.1% and 21.8% for Groups 1 and 3, respectively). In the other principal diagnosis subgroups (Groups 3 and 4), the most frequent CCS disease categories were diseases of the respiratory system (eg, respiratory failure, chronic obstructive pulmonary disease, emphysema), infections/parasitic diseases (eg, septicemia and infections of other organs or systems), injury, and poisoning.

Propensity score-matched results

In-hospital mortality varied from 4% to 25.7% for C-NS infections and from 3% to 23.3% for C-S infections across the 4 subgroups (Fig 2A). The mortality rate was highest in C-NS cases in Group 4 (other principal diagnosis, hospital-onset). Higher mortality was found for hospital-onset subgroups compared with community-onset subgroups. In each subgroup, mortality was higher for C-NS infections than C-S infections (adjusted odds ratios indicated a 6% to 35% increase in risk of mortality), but the differences between C-NS and C-S infections were not statistically significant.
Readmissions occurred in 15.5% to 19.4% of patients with C-NS infections (Fig 2B); the range was 13.5% to 20.4% for C-S infections, with the greatest readmission rate observed in Group 1 (bacterial pneumonia, community-onset). The difference between C-NS and C-S cases was not significant in any of the subgroups. There were no consistent relationships between carbapenem susceptibility status, infection-onset period, or principal diagnosis and the likelihood of readmission.

Mean LOS was 8.9 days to 29.4 days for C-NS cases and 8.3 days to 25.7 days for C-S cases, with the longest LOS observed in Group 4 (29.4 days; 95% confidence interval [CI]: 27.1, 31.9) (Fig 2C). In all subgroups the mean LOS was greater for C-NS versus C-S cases, and this difference was statistically significant for Groups 3 and 4 (+1.5 days; \( P < 0.001 \) and +3.7 days; \( P = 0.006 \), respectively). Mean LOS for hospital-onset cases was either double or triple that of community-onset cases (principal diagnosis of bacterial pneumonia or other, respectively).

The mean total cost incurred by hospitals for each C-NS infection ranged from $14,255 to $81,574, and from $14,220 to $68,797 for each C-S infection (Fig 3A). Group 4 (other principal diagnosis, hospital-onset) accounted for the highest figure in both of these ranges, with the highest overall cost observed for C-NS infections ($81,574; 95% CI: $72,928, $91,245). In all 4 subgroups the cost of C-NS infections was greater than that of C-S infections; this difference was statistically significant for Groups 3 and 4 (+$2681; \( P < 0.001 \) and +$12,777; \( P < 0.01 \), respectively).

The financial impact to the hospital was limited in Groups 1 and 3, with either a net gain or a small loss per case (Fig 3B). Larger losses were observed in Groups 2 and 4, with the largest negative balance associated with C-S infections in Group 4 ($-16,782; 95% CI: -$28,000, -$5,563). This suggests that the payments received for hospital-onset infections are not sufficient to cover their cost, leaving the hospital with a negative balance. In all subgroups, the net
Table 1. Distribution of patient characteristics after propensity score matching.

| Variables, n (%) | Group 1: BP PDX, CO | Group 2: BP PDX, HO | Group 3: Other PDX, CO | Group 4: Other PDX, HO |
|-----------------|---------------------|---------------------|------------------------|------------------------|
|                 | C-NS (n = 101)      | C-S (n = 101)       | C-NS (n = 742)         | C-S (n = 1463)         |
|                 |                     |                     |                        |                        |
| **Sex**         |                     |                     |                        |                        |
| Female          | 52 (51.5)           | 51 (50.5)           | 24 (57.1)              | 21 (50.0)              |
| Male            | 49 (48.5)           | 50 (49.5)           | 18 (42.9)              | 21 (50.0)              |
| **Age group, years** |                     |                     |                        |                        |
| 18–34           | 17 (16.8)           | 21 (20.8)           | 3 (7.1)                | 5 (11.9)               |
| 35–44           | 9 (8.9)             | 7 (6.9)             | 1 (2.4)                | 1 (2.4)                |
| 45–54           | 9 (8.9)             | 8 (7.9)             | 2 (4.8)                | 2 (4.8)                |
| 55–64           | 15 (14.9)           | 12 (11.9)           | 14 (33.3)              | 11 (26.2)              |
| 65–74           | 30 (29.7)           | 36 (35.6)           | 14 (33.3)              | 7 (16.7)               |
| 75–84           | 13 (12.9)           | 13 (12.9)           | 5 (11.9)               | 11 (26.2)              |
| 85 or older     | 8 (7.9)             | 4 (4.0)             | 3 (7.1)                | 5 (11.9)               |
| **Payer**       |                     |                     |                        |                        |
| Medicare        | 51 (50.5)           | 51 (50.5)           | 24 (57.1)              | 23 (54.8)              |
| Medicaid        | 6 (5.9)             | 9 (8.9)             | 5 (11.9)               | 2 (4.8)                |
| Private/other   | 44 (43.6)           | 41 (40.6)           | 13 (31.0)              | 17 (40.5)              |
| **AlaRMS Score** |                     |                     |                        |                        |
| 1st quartile    | 36 (35.6)           | 41 (40.6)           | 15 (35.7)              | 11 (26.2)              |
| 2nd quartile    | 25 (24.8)           | 23 (22.8)           | 4 (9.5)                | 9 (16.7)               |
| 3rd quartile    | 18 (17.8)           | 16 (15.8)           | 6 (14.3)               | 9 (21.4)               |
| 4th quartile    | 22 (21.8)           | 21 (20.8)           | 17 (40.5)              | 15 (35.7)              |
| **Number of hospital admissions in the 90 days before index admission** | | | | |
| 0               | 59 (58.4)           | 59 (58.4)           | 26 (61.9)              | 27 (64.3)              |
| 1               | 26 (25.7)           | 25 (24.8)           | 11 (26.2)              | 12 (28.6)              |
| >1              | 16 (15.8)           | 17 (16.8)           | 5 (11.9)               | 3 (7.1)                |
| **Intensive care unit admission status** | | | | |
| No              | 69 (68.3)           | 69 (68.3)           | 31 (73.8)              | 32 (76.2)              |
| Yes             | 32 (31.7)           | 32 (31.7)           | 11 (26.2)              | 10 (23.8)              |
| **Mechanical ventilation status** | | | | |
| No              | 70 (69.3)           | 74 (73.3)           | 29 (69.0)              | 30 (71.4)              |
| Yes             | 31 (30.7)           | 27 (26.7)           | 13 (31.0)              | 12 (28.6)              |
| **Exposure risk (# of days from admission to onset of infection)** | | | | |
| 1st quartile    | N/A                 | N/A                 | 22 (54.2)              | 12 (28.6)              |
| 2nd quartile    | N/A                 | N/A                 | 3 (7.1)                | 6 (14.3)               |
| 3rd quartile    | N/A                 | N/A                 | 6 (14.3)               | 12 (28.6)              |
| 4th quartile    | N/A                 | N/A                 | 11 (26.2)              | 12 (28.6)              |
| **Type of gram-negative organism** | | | | |
| *Pseudomonas aeruginosa* | 79 (78.2) | 83 (82.2) | 34 (81.0) | 34 (81.0) |
| Polymicrobial   | 14 (13.9)           | 12 (11.9)           | 0 (0)                  | 4 (9.5)                |
| Other gram-negative | 8 (7.9) | 6 (5.9) | 8 (19.0) | 4 (9.5) |
| **PDX-based CCS disease category** | | | | |
| Diseases of the respiratory system | N/A | N/A | N/A | 163 (22.0) |
| Endocrine, nutritional, and metabolic diseases and immunity disorders | N/A | N/A | N/A | 219 (29.5) |
| Infectious and parasitic diseases | N/A | N/A | N/A | 192 (25.9) |
| Injury and poisoning | N/A | N/A | N/A | 62 (8.4) |
| Diseases of the circulatory system | N/A | N/A | N/A | 28 (3.8) |

(Continued)
gain or loss was worse with C-S infections than C-NS infections, although the differences between C-S and C-NS cases were not statistically significant.

**Discussion**

The burden attributable to respiratory infections has been well-described in the literature; however, few studies have focused specifically on the impact of gram-negative respiratory C-NS infections in comparison with C-S infections, and there are no studies of which we are aware that have evaluated both clinical and economic outcomes and the resulting financial impact to the hospital.

The in-hospital mortality rates reported here are broadly comparable to others in the literature, with previously reported rates ranging from 14.5% to 60.6% for C-NS isolates [14–16,23,24]. The highest mortality rate in this study (25.7%) was in patients with other conditions (a principal diagnosis other than bacterial pneumonia) who developed a concomitant respiratory infection during their hospital stay. This analysis also showed that the risk of death was numerically higher for C-NS versus C-S infections (although not statistically significantly higher), indicating that a concomitant respiratory infection that is C-NS may be more serious for patients than C-S infections. Future studies with larger sample sizes would be needed to further examine the mortality burden. For 30-day readmission, rates were generally high (up to 20.4%); however, no clear trends relating to C-NS status, principal diagnosis, or onset of infection were evident from this analysis.

Both LOS and cost ranged widely across the 4 subgroups; however, LOS is likely a key component of the overall cost. Our findings for gram-negative infections fall within the expected

Table 1. (Continued)

| Variables, n (%) | Group 1: BP PDX, CO | Group 2: BP PDX, HO | Group 3: Other PDX, CO | Group 4: Other PDX, HO |
|------------------|----------------------|---------------------|-----------------------|-----------------------|
| Diseases of the digestive system | C-NS (n = 101) C-S (n = 101) | C-NS (n = 42) C-S (n = 42) | C-NS (n = 742) C-S (n = 742) | C-NS (n = 463) C-S (n = 463) |
| Neoplasms | N/A N/A | N/A N/A | 16 (2.2) 12 (1.6) | 31 (6.7) 32 (6.9) |
| Missing PDX | N/A N/A | N/A N/A | 8 (1.1) 10 (1.3) | 18 (3.9) 17 (3.7) |
| All other CCS | N/A N/A | N/A N/A | 20 (2.7) 16 (2.2) | 16 (3.5) 12 (2.6) |

**Hospital teaching status**

- Nonteaching: 60 (59.4) 61 (60.4) 34 (81.0) 34 (81.0) 354 (47.7) 365 (49.2) 264 (57.0) 269 (58.1)
- Teaching: 41 (40.6) 40 (39.6) 8 (19.0) 8 (19.0) 388 (52.3) 377 (50.8) 199 (43.0) 194 (41.9)

**Hospital size (number of beds)**

- ≤300: 34 (33.7) 25 (24.8) 18 (42.9) 15 (35.7) 144 (19.4) 133 (17.9) 75 (16.2) 64 (13.8)
- >300: 67 (66.3) 76 (75.2) 24 (57.1) 27 (64.3) 598 (80.6) 609 (82.1) 388 (83.8) 399 (86.2)

**Geographic location (regions)**

- Midwest: 17 (16.8) 13 (12.9) 6 (14.3) 1 (2.4) 101 (13.6) 84 (11.3) 92 (19.9) 82 (17.7)
- Northeast: 1 (1.0) 0 (0) 2 (4.8) 2 (4.8) 30 (4.0) 29 (3.9) 17 (3.7) 18 (3.9)
- South: 72 (71.3) 78 (77.2) 30 (71.4) 37 (88.1) 562 (75.7) 589 (79.4) 326 (70.4) 342 (73.9)
- West: 11 (10.9) 10 (9.9) 4 (9.5) 2 (4.8) 49 (6.6) 40 (5.4) 28 (6.0) 21 (4.5)

All post-matching variables were well-balanced with all P values >0.05, indicating no significant differences between C-NS and C-S cohorts within each of the 4 groups (see S2 Table for pre- versus post-matching details). ALaRMS, Acute Laboratory Risk of Mortality Score; BP, bacterial pneumonia; C-NS, carbapenem nonsusceptible; C-S, carbapenem susceptible; CCS, Clinical Classification Software; CO, community-onset; HO, hospital-onset; N/A, not applicable; PDX, principal diagnosis.

aALaRMS quartile cutoff was based on the distribution within each of the 4 subgroups prior to propensity score matching.

bAs determined by CCS software.

https://doi.org/10.1371/journal.pone.0229393.t001
Burden of carbapenem-NS respiratory infections

A

Mortality, %

| Group | C-NS | C-S |
|-------|------|-----|
| Group 1: BP PDX, CO | 4.0% | 3.0% |
| Group 2: BP PDX, HO | 14.3% | 11.9% |
| Group 3: Other PDX, CO | 8.5% | 8.4% |
| Group 4: Other PDX, HO | 25.7% | 23.3% |

N

| Group | N |
|-------|---|
| Group 1: BP PDX, CO | 101 |
| Group 2: BP PDX, HO | 42 |
| Group 3: Other PDX, CO | 742 |
| Group 4: Other PDX, HO | 463 |

Adjusted OR

| Group | (95% CI) |
|-------|----------|
| Group 1: BP PDX, CO | 1.35 (0.46-3.94) |
| Group 2: BP PDX, HO | 1.23 (0.41-3.69) |
| Group 3: Other PDX, CO | 1.06 (0.75-1.50) |
| Group 4: Other PDX, HO | 1.12 (0.86-1.47) |

P-value

| Group | P-value |
|-------|---------|
| Group 1: BP PDX, CO | 0.586 |
| Group 2: BP PDX, HO | 0.708 |
| Group 3: Other PDX, CO | 0.746 |
| Group 4: Other PDX, HO | 0.405 |

B

30-day Readmission, %

| Group | C-NS | C-S |
|-------|------|-----|
| Group 1: BP PDX, CO | 15.5% | 20.4% |
| Group 2: BP PDX, HO | 19.4% | 13.5% |
| Group 3: Other PDX, CO | 18.7% | 17.9% |
| Group 4: Other PDX, HO | 17.7% | 18.3% |

N

| Group | N |
|-------|---|
| Group 1: BP PDX, CO | 97 |
| Group 2: BP PDX, HO | 36 |
| Group 3: Other PDX, CO | 679 |
| Group 4: Other PDX, HO | 344 |

Adjusted OR

| Group | (95% CI) |
|-------|----------|
| Group 1: BP PDX, CO | 0.71 (0.37-4.88) |
| Group 2: BP PDX, HO | 1.52 (0.34-6.72) |
| Group 3: Other PDX, CO | 1.12 (0.86-1.47) |
| Group 4: Other PDX, HO | 1.58 (1.14-2.20) |

P-value

| Group | P-value |
|-------|---------|
| Group 1: BP PDX, CO | 0.307 |
| Group 2: BP PDX, HO | 0.583 |
| Group 3: Other PDX, CO | 0.407 |
| Group 4: Other PDX, HO | 0.838 |

C

Estimated Mean (± 95% CI) LOS, days

| Group | C-NS | C-S |
|-------|------|-----|
| Group 1: BP PDX, CO | 8.9 | 9.8 |
| Group 2: BP PDX, HO | 8.6 | 8.3 |
| Group 3: Other PDX, CO | 16.5 | 18.5 |
| Group 4: Other PDX, HO | 29.4 | 25.7 |

P

| Group | P |
|-------|---|
| Group 1: BP PDX, CO | 0.708 |
| Group 2: BP PDX, HO | 0.249 |
| Group 3: Other PDX, CO | 0.001 |
| Group 4: Other PDX, HO | 0.006 |
range of costs from the literature (the total cost of hospital-acquired respiratory infections of any kind is estimated to range from $22,300 to $99,598) [25–27]. In all subgroups, LOS and costs for C-NS infections were higher than for C-S infections, with a statistically significant C-NS–attributable burden observed in both other principal diagnosis subgroups. As with mortality, the highest burden for LOS and cost was borne by patients with other principal diagnoses who developed a respiratory infection once admitted to the hospital. These patients therefore represent an important target for anyone wishing to effectively manage the burden associated with gram-negative respiratory infections.

Regarding the balance of costs and payment received, we showed that hospitals lose money for each patient with a hospital-onset infection, but lose a smaller amount for C-NS infections compared with C-S infections (these differences were not statistically significant). Given the greater complexity of C-NS infections and the reduced number of appropriate treatment options, this result is perhaps surprising. Investigating and understanding the nature of payer reimbursement to hospitals for C-NS infections may provide some insight.

The strengths of this study include the large number of patients with positive respiratory isolate cultures from diverse hospital settings (eg, small versus large, teaching versus nonteaching). In addition, the propensity score matching method enabled us to balance potential confounding factors for the outcomes and minimize possible sources of bias. Nevertheless, propensity score matching has its own limitations, which could potentially affect outcomes. Approximately 10% of unmatched C-NS cases were dropped from further analysis. Identification of a subset of patients with ICD-9-CM codes indicative of bacterial pneumonia was intended to reduce the potential for including patients who are colonized with gram-negative organisms but who do not have a clinically meaningful infection. However, we only identified a relatively low number of patients with a principal diagnosis of bacterial pneumonia and a C-NS isolate (n = 155). The lack of secondary diagnoses in the dataset limited further confirmation of diagnosis codes. Thus, we were not able to rule out the possibility that positive culture results were due to colonization. Nevertheless, given the worse outcomes observed even for those with other diagnoses as the primary reason for hospital admission, there is a good likelihood that these patients had a true infection. Locally applied microbiological assessments and interpretation may vary from one institution to the next, which can be considered a limitation to the study. The use of ICD-9-CM codes may also be a limitation to this study, in that codes are primarily used for billing purposes and may be over-used, under-used or misused, and therefore do not accurately capture the patient’s clinical situation. Chart review and radiographic imaging confirmation, in conjunction with ICD-9-CM codes and culture confirmation, would more accurately and fully characterize each case. In addition, analysis of antibiotic utilization before and during the index hospitalization may help to identify patients with clinically relevant infections and provide insights into any relationship between antibiotic prescribing practices and observed clinical and economic outcomes. Further analyses that identify the key drivers of outcomes in this patient population, such as patient characteristics or the relationship between payer type and payments received, would also be of great interest.

In conclusion, C-NS–attributable burden was observed in propensity score-matched patients with culture-confirmed gram-negative respiratory infections for mortality (risk of death numerically increased by up to 35%), LOS (significantly extended by up to 3.7 days), and cost (significant additional costs in excess of $12,000).
Fig 3. Total cost (A) and net gain/loss (B) by propensity score-matched patient cohorts. BP, bacterial pneumonia; C-NS, carbapenem nonsusceptible; C-S, carbapenem susceptible; CI, confidence interval; CO, community-onset; HO, hospital-onset; PDX, principal diagnosis; USD, United States dollars.

https://doi.org/10.1371/journal.pone.0229393.g003
greatest in patients admitted to hospital with other underlying conditions who then developed a hospital-onset respiratory infection. These data illustrate how carbapenem nonsusceptibility can increase the burden of respiratory infections, especially in patients hospitalized with potentially complex and serious clinical conditions.

Supporting information

S1 Table. Principal diagnosis codes (ICD-9-CM). CMS, Centers for Medicare and Medicaid Services; ICD-9-CM, International Classification of Diseases, Ninth Revision, Clinical Modification; NOS, not otherwise specified; VAP, ventilator-associated pneumonia.

S2 Table. Pre- and post-matching of baseline characteristics: Respiratory groups 1, 2, 3, and 4. Respiratory group 2 had the fewest patients so variable groupings were modified from respiratory groups 1, 3, and 4 in order to conduct statistical tests. ALaRMS, Acute Laboratory Risk of Mortality Score; C-NS, carbapenem nonsusceptible; C-S, carbapenem susceptible; CCS, Clinical Classification Software; ICU, intensive care unit; PDX, principal diagnosis.

Acknowledgments

The authors wish to thank Dr. Richard S. Johannes for his clinical insight and contribution at the early stage of this study, and Stephen Kurtz for his dedicated contribution to database management and programming assistance. The authors would also like to thank Dr. Amanda Paschke and Dr. Pamela Moise for their input into the development of the ICD-9-CM code lists. Editorial assistance was provided by Robert Schupp, PharmD, CMPP, of The Lockwood Group.

Author Contributions

Conceptualization: Ying P. Tabak, Anita Sung, Gang Ye, Vikas Gupta, Eilish McCann.
Data curation: Ying P. Tabak, Gang Ye, Latha Vankeepuram, Vikas Gupta.
Formal analysis: Ying P. Tabak, Gang Ye.
Funding acquisition: Anita Sung, Eilish McCann.
Investigation: Ying P. Tabak, Anita Sung, Vikas Gupta, Eilish McCann.
Methodology: Ying P. Tabak, Anita Sung, Vikas Gupta, Eilish McCann.
Project administration: Ying P. Tabak, Eilish McCann.
Resources: Ying P. Tabak, Gang Ye, Latha Vankeepuram, Vikas Gupta.
Software: Ying P. Tabak, Gang Ye, Latha Vankeepuram.
Supervision: Ying P. Tabak.
Validation: Ying P. Tabak, Gang Ye, Latha Vankeepuram.
Visualization: Ying P. Tabak, Gang Ye, Latha Vankeepuram.
Writing – original draft: Ying P. Tabak, Anita Sung, Eilish McCann.
Writing – review & editing: Ying P. Tabak, Anita Sung, Gang Ye, Latha Vankeepuram, Vikas Gupta, Eilish McCann.
References
1. Kochanek KD, Murphy SL, Xu J, Tejada-Vera B. Deaths: final data for 2014. Natl Vital Stat Rep. 2016; 65(4):1–122. PMID: 27378572
2. Torio CM, Moore BJ. National inpatient hospital costs: the most expensive conditions by payer, 2013 (Hcup Statistical Brief #204). May 2016 [cited 20 November 2017]. Available from: https://www.hcup-us.ahrq.gov/reports/statbriefs/hcupstatb204 MostExpensiveHospitalConditions.jsp
3. Pluntner A, Wier LM, Stocks C. Statistical Brief #162: most frequent conditions in U.S. hospitals, September 2013 [cited 2 October 2017]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK169248/pdf/Bookshelf_NBK169248.pdf
4. Wuerth BA, Bonnewell JP, Wiemken TL, Arnold FW. Trends in pneumonia mortality rates and hospitalizations by organism, United States, 2002–2011. Emerg Infect Dis. 2016; 22(9):1624–1627. https://doi.org/10.3201/eid2209.150980 PMID: 27632154
5. Jones RN. Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Clin Infect Dis. 2010; 51(Suppl 1):S81–S87. https://doi.org/10.1086/653053 PMID: 20597676
6. Djordjevic ZM, Folic MM, Jankovic SM. Distribution and antibiotic susceptibility of pathogens isolated from adults with hospital-acquired and ventilator-associated pneumonia in intensive care unit. J Infect Public Health. 2017; 10(6):740–744. https://doi.org/10.1016/j.jiph.2016.11.016 PMID: 28198513
7. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007; 44(Suppl 2):S27–S72.
8. Kall AC, Mettersky ML, Klimpas M, Muscedere J, Sweeney DA, Palmer LB, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016; 63(5):e61–e111. https://doi.org/10.1093/cid/ciw353 PMID: 27418577
9. Antimicrobial Resistance Global Report on Surveillance. June 2014 [cited 2 October 2017]. Available from: http://apps.who.int/iris/bitstream/10665/112642/1/9789241564748_eng.pdf?ua=1
10. Untreatable: Report by CDC details today’s drug-resistant health threats. September 2013 [cited 2 October 2017]. Available from: https://www.cdc.gov/media/releases/2013/p0916-untreatable.html
11. Thaden JT, Lewis SS, Hazen KC, Hulsko E, Fowler VG Jr, Moehring RW, et al. Rising rates of carbapenem-resistant enterobacteriaceae in community hospitals: a mixed-methods review of epidemiology and microbiology practices in a network of community hospitals in the southeastern United States. Infect Control Hosp Epidemiol. 2014; 35(8):978–983. https://doi.org/10.1086/677157 PMID: 25026612
12. Sader HS, Farrel DJ, Flamik RK, Jones RN. Antimicrobial susceptibility of gram-negative organisms isolated from patients hospitalised with pneumonia in U.S. and European hospitals: results from the SENTRY Antimicrobial Surveillance Program, 2009–2012. Int J Antimicrob Agents. 2014; 43(4):328–334. https://doi.org/10.1016/j.ijantimicag.2014.01.007 PMID: 24630306
13. Bielke LR, Cottreau JM, Thompson DJ, Filipke RL, O’Donnell JN, Lasco TM, et al. Outcomes and risk factors for mortality among patients treated with carbapenem for Klebsiella spp. bacteremia. PLoS One. 2015; 10(11):e0143845. https://doi.org/10.1371/journal.pone.0143845 PMID: 26618357
14. Muggeo A, Guillard T, Barbe C, Thierry A, Bajolet O, Vernet-Garnier V, et al, on behalf of CARBAFEST Group. Factors associated with carriage of carbapenem-non-susceptible Enterobacteriaceae in North-Eastern France and outcomes of infected patients. J Antimicrob Chemother. 2017; 72(5):1496–1501. https://doi.org/10.1093/jac/dkw590 PMID: 28158526
15. Wu PF, Chuang C, Su CF, Lin YT, Chan YJ, Wang FD, et al. High minimum inhibitory concentration of imipenem as a predictor of fatal outcome in patients with carbapenem-non-susceptible Klebsiella pneumoniae. Sci Rep. 2016; 6:32665. https://doi.org/10.1038/srep32665 PMID: 27585787
16. Zilberberg MD, Nathanson BH, Sulham K, Fan W, Shorr AF. Carbapenem resistance, inappropriate empiric treatment and outcomes among patients hospitalized with Enterobacteriaceae urinary tract infection, pneumonia and sepsis. BMC Infect Dis. 2017; 17(1):279. https://doi.org/10.1186/s12879-017-2383-z PMID: 28415969
17. Gross AE, Johannes RS, Gupta V, Tabak YP, Srinivasan A, Bleasdale SC. The effect of a piperacillin/tazobactam shortage on antimicrobial prescribing and Clostridium difficile risk in 88 US medical centers. Clin Infect Dis. 2017; 65(4):613–618. https://doi.org/10.1093/cid/cix379 PMID: 28444166
18. Tabak YP, Zilberberg MD, Johannes RS, Sun X, McDonald LC. Attributable burden of hospital-onset Clostridium difficile infection: a propensity score matching study. Infect Control Hosp Epidemiol. 2013; 34(6):588–596. https://doi.org/10.1086/670621 PMID: 23651889
19. Zilberberg MD, Tabak YP, Sievert DM, Derby KG, Johannes RS, Sun X, et al. Using electronic health information to risk-stratify rates of Clostridium difficile infection in US hospitals. Infect Control Hosp Epidemiol. 2011; 32(7):649–655. https://doi.org/10.1086/660360 PMID: 21666394

20. Clinical Classifications Software (CCS) for ICD-9-CM. March 2017 [cited 26 September 2017]. Available from: https://www.hcup-us.ahrq.gov/toolssoftware/ccs/ccs.jsp

21. Tabak YP, Sun X, Nunez CM, Johannes RS. Using electronic health record data to develop inpatient mortality predictive model: Acute Laboratory Risk of Mortality Score (ALaRMS). J Am Med Inform Assoc. 2014; 21(13):455–463. https://doi.org/10.1136/amiajnl-2013-001790 PMID: 24097807

22. Parsons LS. Reducing bias in a propensity score matched-pair sample using Greedy matching techniques. Presented at the Twenty-Sixth Annual SAS Users Group International Conference. 2001: Paper 214–26.

23. Gutiérrez-Gutiérrez B, Salamanca E, de Cueto M, Hsueh PR, Viale P, Paño-Pardo JR, et al. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infect Dis. 2017; 17(7):726–734. https://doi.org/10.1016/S1473-3099(17)30228-1 PMID: 28442293

24. Mataseje LF, Abdesselam K, Vachon J, Mitchel R, Bryce E, Roscoe D, et al. Results from the Canadian Nosocomial Infection Surveillance Program on Carbapenemase-Producing Enterobacteriaceae, 2010 to 2014. Antimicrob Agents Chemother. 2016; 60(11):6787–6794. https://doi.org/10.1128/AAC.01359-16 PMID: 27600052

25. Eber MR, Laxminarayan R, Perencevich EN, Malani A. Clinical and economic outcomes attributable to health care-associated sepsis and pneumonia. Arch Intern Med. 2010; 170(4):347–353. https://doi.org/10.1001/archinternmed.2009.509 PMID: 20177037

26. Kollef MH, Hamilton CW, Ernst FR. Economic impact of ventilator-associated pneumonia in a large matched cohort. Infect Control Hosp Epidemiol. 2012; 33(3):250–256. https://doi.org/10.1086/664049 PMID: 22314062

27. Zimlichman E, Henderson D, Tamir O, Franz C, Song P, Yamin CK, et al. Health care-associated infections: a meta-analysis of costs and financial impact on the US health care system. JAMA Intern Med. 2013; 173(22):2039–2046. https://doi.org/10.1001/jamainternmed.2013.9763 PMID: 23999949